Atazanavir: A novel inhibitor of HIV-protease in haemodialysis [8]

Nephrology Dialysis Transplantation

Volumn 20, Issue 4, 2005, Pages 852-853

  Izzedine, Hassane ^a   Launay Vacher, Vincent ^a   Peytavin, Gilles ^b   Valantin, Marc Antoine ^a   Deray, Gilbert ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; CREATININE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ANAMNESIS; ANURIA; AREA UNDER THE CURVE; CASE REPORT; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; FOCAL GLOMERULOSCLEROSIS; HEMODIALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; KIDNEY TUBULE DISORDER; LETTER; LIVER TOXICITY; MALE; NAUSEA; PRIORITY JOURNAL; VOMITING;

HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RENAL DIALYSIS;

EID: 17144419284     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh684     Document Type: Letter

References (8)

1. Goldsmith DR, Perry CM. Atazanavir. Drugs 2003; 63: 1679-1693
2. Elston AC, Bayliss MK, Park GR. Effect of renal failure on drug metabolism by the liver. Br J Anaesth 1993; 71: 282-290
3. Moyle GJ, Baldwin C. Lipid abnormalities during saquinavir soft-gel-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr 1999; 21: 423-424
4. Purnell JQ, Zambon A, Knopp RH et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000; 14: 51-57
5. Hocher B, Ziebig R, Altermann C et al. Different impact of biomarkers as mortality predictors among diabetic and non-diabetic patients undergoing hemodialysis. J Am Soc Nephrol 2003; 14: 2329-2337
6. Murphy RL, Sanne I, Cahn P et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003; 17: 2603-2614
7. HD. J Am Soc Nephrol 2004; 15: 630A (abstract SU-PO441)
8. Tackett D, Child M, Argarwala S et al. Atazanavir (ATV): a summary of two pharmacokinetic (PK) drug interaction studies in healthy subjects (poster no. 543). In: 10th Conference on Retroviruses and Opportunistic Infections, 10-14 February 2001, Boston, MA, USA